Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Alizyme80 enrolled

Overview

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Obesity

Interventions

ATL-962DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Obese, otherwise-healthy subjects * Body mass index 30-45kg/m2 Exclusion Criteria: * Women who are pregnant or breast feeding * Any drug treatment within 2 weeks of commencement of dosing in this study

Locations (1)

SFBCI

Miami, Florida, United States

Outcomes

Primary Outcomes

Pharmacokinetics of metabolites of ATL-962

Secondary Outcomes

Effect of ATL-962 on faecal fat excretion

Safety and tolerability of ATL-962

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.